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a b s t r a c t
In response to the sharp rise in the global burden caused by dengue virus (DENV) over the last few dec-
ades, the WHO has set out three specific key objectives in its disease control strategy: (i) to estimate the
true burden of dengue by 2015; (ii) a reduction in dengue mortality by at least 50% by 2020 (used as a
baseline); and (iii) a reduction in dengue morbidity by at least 25% by 2020. Although various elements
will all play crucial parts in achieving this goal, from diagnosis and case management to integrated
surveillance and outbreak response, sustainable vector control, vaccine implementation and finally oper-
ational and implementation research, it seems clear that new tools (e.g. a safe and effective vaccine and/
or effective vector control) are key to success. The first dengue vaccine was licensed in December 2015,
Dengvaxia (CYD-TDV) developed by Sanofi Pasteur. The WHO has provided guidance on the use of CYD-
TDV in endemic countries, for which there are a variety of considerations beyond the risk–benefit eval-
uation done by regulatory authorities, including public health impact and cost-effectiveness. Population-
level vaccine impact and economic and financial aspects are two issues that can potentially be considered
by means of mathematical modelling, especially for new products for which empirical data are still lack-
ing. In December 2014 a meeting was convened by the WHO in order to revisit the current status of den-
gue transmission models and their utility for public health decision-making. Here, we report on the main
points of discussion and the conclusions of this meeting, as well as next steps for maximising the use of
mathematical models for vaccine decision-making.
1. Background
Over the last few decades dengue has become the most impor-
tant and wide-spread, vector-borne viral infection affecting
humans [1,2]. The geographic expansion of dengue’s two mosquito
vectors, Aedes aegypti and Ae. albopictus, together with ongoing
globalisation and urbanisation have resulted in more frequent
and bigger epidemic outbreaks as well as endemic establishment
of dengue in previously unaffected areas.
Infection with one of dengue’s four antigenically related sero-
types (DENV1-4) can result in a systemic viral illness, with symp-
toms lasting for around 2–7 days. Infection with one serotype is
assumed to provide life-long, homotypic immunity but might leave
the individual more vulnerable to develop clinically severe out-
comes upon secondary, heterotypic infection [3–5]. The common-
est severe outcome is hypovolemic shock, called (Dengue Shock
Syndrome (DSS)) and is precipitated by a vascular leakage syn-
drome that manifests between days 4–7 of illness. Treatment of
dengue is limited to supportive care and when done carefully can
decrease mortality to <0.5% of hospitalised cases.
In the absence of effective vaccines, current control efforts
against DENV transmission are targeted against the mosquito
vectors, either through direct measures (e.g. application of
insecticides) or through the limitation of vector breeding habitat
(e.g. environmental management). Although vector control efforts
can show reductions in entomological indicators, there is a limited
evidence base to demonstrate effectiveness against dengue disease
of any of these public health interventions [6]. There is clear
consensus that new tools are needed to prevent and control
dengue, including the development of a safe and efficacious
vaccine to control dengue. The most advanced vaccine candidate
to date is Sanofi Pasteur’s recombinant live attenuated tetravalent
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dengue vaccine (CYD-TDV), which has been evaluated in Phase III
clinical efficacy trials across various endemic countries in Asia
and Latin America [7,8]. The vaccine has recently obtained licen-
sure in Mexico, the Philippines, Brazil, El Salvadore and Paraguay,
with applications submitted in several other endemic countries.
Overall vaccine efficacy of CYD-TDV was estimated to be around
60% against virological confirmed dengue (VCD), with high levels
of protection offered against hospitalisation and severe disease
[7,8]. However, marked variations were observed between ende-
mic settings and between individual serotypes, with efficacies
ranging from 35% (in the case of DENV2) to well over 70% (for
DENV3 and DENV4). A significant difference in vaccine efficacy
was also observed between naive individuals and individuals with
pre-existing antibodies to one or more dengue serotypes, where
naïve individuals were on average twice as likely to experience a
symptomatic break-through infection. Recent pooled analyses of
the first 2–3 years of long-term follow-up provided further sup-
portive evidence of efficacy against hospitalised dengue in children
9 years of age or older [9]. There was however a concerning signal
for increased hospitalised dengue illness amongst participants
2–5 years of age (RR = 7.45, 95%CI 1.15, 313.80). There are multiple
hypotheses that could explain this increased risk [10], including
age-specific susceptibility to severe disease, suboptimal vaccine
immunogenicity and/or waning immunity in vaccine recipients
who were seronegative for dengue viruses at baseline, and
temporal clustering of cases in the CYD group [11]. As a result,
Sanofi Pasteur has limited the age indication to individuals 9+
years of age.
As the vaccine is licensed, countries are faced with decisions
about whether and how to introduce a dengue vaccine, and what
the public health impact might be, both in terms of the reduction
in disease burden and potential risks. Depending on disease epi-
demiology, vaccine price, and other factors, these decisions may
not be straightforward. Mathematical models can provide policy
makers with additional potential considerations to inform their
decisions on optimal vaccine use in the context of the broader den-
gue control program. To this end, a meeting was held at the WHO
in 2014 in order to revisit the current status of dengue intervention
models and to discuss their utility for public health decision-
making. Here we summarise the meeting with regards to the
challenges faced by modellers and health policy makers identified
during this meeting.
2. Role for modelling in shaping national and international
recommendations on dengue vaccination
Mathematical models have long been recognised as useful tools
for addressing public health questions. Their ability to both sim-
plify and elucidate complex relationships have contributed greatly
to our understanding of epidemiological concepts, including the
basic reproductive number (R0), herd immunity and vaccine
escape. Consequently, models of vaccination are used at both
national and global levels to inform decision making. Often, several
models exist which examine the same vaccine-related decision
question using different input data sources, modelling methods
and levels of complexity. Comparative modelling exercises can be
used to understand the similarities and differences between differ-
ent models in order to draw overall conclusions about the likely
impact of vaccination strategies [12]. Such exercises are useful to
inform countries, which rely on the results of models but do not
have the technical capacity to appraise an entire suite of models.
Mathematical models can also be used to inform global recom-
mendations and policies about vaccines, which need to take into
account a variety of settings and potential strategies. For instance,
WHO is advised by the Strategic Advisory Group of Experts (SAGE)
on Immunization to make global vaccine-related recommenda-
tions, with input frommodels that have been appraised by its advi-
sory committee, the Immunization and Vaccines related
Implementation Research Advisory Committee (IVIR-AC). Recently,
the outputs of a coordinated mathematical model comparison of
the potential impact of the RTS, S malaria vaccine were used in
the decision-making process for WHO recommendations on the
use of this vaccine [13,14]. The modelling revealed that despite
the overall low efficacy, the vaccine could have a substantial addi-
tional public health impact across a broad range of settings repre-
sentative of malaria parasite prevalence in Africa in the presence of
other ongoing interventions. It also provided indication on cost-
effectiveness and performance in various transmission settings.
WHO has also used comparative modelling to inform country
decision-makers on the use of cost-effectiveness tools for other
vaccines, including pneumococcal vaccines, rotavirus and human
papillomavirus vaccines [15–18].
With a similar exercise now under way with regards to a
dengue vaccine, it is important to note that the level of certainty
we can have in model conclusions ultimately depends on the avail-
ability of suitable data as well as our understanding of the biolog-
ical and epidemiological mechanisms driving disease dynamics.
Given currently available data dengue disease dynamics and
performance of dengue prevention tools (i.e. vaccine and vector
control effectiveness), there are several policy questions that can
be well-informed by mathematical modelling, such as: what is
the impact of different vaccination strategies on disease, taking
into consideration different target age groups, variable vaccine effi-
cacies and/or vaccine coverage levels? Or what is the cost-
effectiveness of different strategies for a dengue vaccination pro-
gram? There is also substantial programmatic interest in exten-
sions of mathematical modelling to other aspects, such as the
impact of integrated vaccination/vector control programs or the
change in disease dynamics and dengue epidemiology following
vaccine introduction. However, due to the current limitations in
empiric data on vaccine performance and mechanism of action,
many of these should be considered as exploratory at this stage
and with great uncertainties attached to their outputs.
3. Model and other uncertainties
There is an appreciable degree of freedom, by which biological
and ecological phenomena can be described mathematically. Con-
sequently, models of dengue transmission and/or intervention can
be found in various shapes and sizes, ranging from differential
equation models to spatially explicit agent-based approaches that
include most of the known ecological and immunological determi-
nants influencing the transmission cycle of dengue; for an over-
view of recent models investigating dengue epidemiology and
control see e.g. [19–21]. Regardless of the wide range of modelling
taken to investigate the potential impact of individual or inte-
grated control strategies on reducing the burden of disease, an
important issue that was highlighted during the meeting was that
of uncertainties, not only those relating to underlying model
assumptions but also those relating to vaccine action and the
(long-term) effectiveness of vector control. That is, ambiguities still
exist relating to the various factors affecting dengue virus
transmission and immunity, which mostly revolve around the
short and long-term effects of a primary dengue virus infection
on the immuno-epidemiology and pathology of subsequent
infections. For example, it is commonly assumed that following
an infection the host remains fully protected against reinfection
by all other serotypes for a certain length of time (between
6 months and 2 years) [22–24] and that due to the phenomenon
of antibody-dependent enhancement, severe infection outcomes
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are not only much more likely during secondary, heterologous
infections but also much more transmissible. This view has
recently been challenged, however [25]; and with the majority of
dengue infections going unreported and much of the available epi-
demiological data based on clinical cases only, robust empirical
evidence that conclusively relate age, prior exposure, infection
pathology and viral transmission is still lacking.
Similar uncertainties also apply to vaccine induced protection,
such that data from the recent trials do not allow us to discrimi-
nate whether the vaccine offers any protection against infection
or against clinical disease only, or what effect breakthrough infec-
tions have on the immune status of the vaccinees. The vaccine tri-
als further highlighted significant uncertainties associated with a
partially efficacious vaccine. That is, the observed differences in
vaccine efficacy between individuals that were seropositive or
seronegative at baseline indicate that serostatus is an important
consideration and possibly relevant for other live attenuated den-
gue vaccine candidates, too. For CYD-TDV in particular it will
therefore be important to investigate vaccine efficacy under differ-
ent levels of transmission intensity and target age groups for vac-
cination to maximise impact whilst preventing adverse outcomes,
given the reported elevated risk of hospitalisation with dengue
amongst the 2–5 yr old CYD-TDV vaccine recipients in the 3rd year
post-vaccine initiation. More generally, though, while the trans-
mission models themselves can be applied across all dengue vac-
cine candidates, the mode of action of the different vaccines may
need to be considered differently, based on the available immuno-
genicity and efficacy data.
Given these uncertainties it is imperative that thorough model
sensitivity analyses are to be carried out [26], not only to gain a
better understanding of the full range in qualitative and quantita-
tive model behaviour under parameter changes, but also to high-
light the most important knowledge gaps. In that respect,
sensitivity analyses need to go beyond finding and reporting on
the most influential parameters but crucially have to incorporate
uncertainties in parameter values as well as in the underlying
model structure and assumptions [27].
4. Model comparisons
To develop global policy recommendations, SAGE constituted a
Working Group on Dengue Vaccines, for which a key input for
decision-making is the predicted disease impact and cost-
effectiveness of a dengue immunization program based on mathe-
matical modelling. SAGE reviewed CYD-TDV as well as model-
based predictions of public health and economic impact in April
2016. SAGE recommended countries consider introduction of the
vaccine only in geographic settings (national or subnational) with
high endemicity, with seroprevalence thresholds informed by the
mathematical modelling analyses (see http://www.who.int/immu-
nization/sage/meetings/2016/april/SAGE_April_2016_Meeting_
Web_summary.pdf?ua=1&ua=1). A WHO vaccine position paper
outlining WHO recommendations is expected to be published in
July 2016.
The above mentioned uncertainties underlying the immuno-
epidemiology of dengue and vaccine action will undoubtedly have
significant effects on the models’ ability to make quantitative and
robust predictions about the impact of integrated control
measures. In light of these findings, the WHO initiated a model
comparison exercise in April 2015 [28,29] with the aim of quanti-
fying the health and economic impact of a dengue vaccination
campaign based on our current understanding of the action of
the CYD-TDV candidate. Such a model comparison exercise adds
significant value towards an evidence-based decision making
process. Not only does it yield a much better understanding of
the features, similarities and differences between models, it also
crucially enhances communication between the modelling groups,
and between modellers and other scientists, stakeholders and
policy-makers. The results from this exercise, based on eight mod-
els using standardised input datasets representing a variety of
dengue-endemic settings, have now been appraised by both IVIR-
AC and SAGE’s Dengue Working Group, with the detailed results
expected to be published later this year.
At this stage, however, emphasis is predominantly placed on
vaccination impact without explicitly taking vector control mea-
sures into consideration, due to the added complexities and uncer-
tainties underlying the large-scale application and effectiveness of
vector control. Nevertheless, more data, especially from the CYD-
TDV long-term follow-up studies will become available in the near
future. It is thus expected that some of these uncertainties will get
resolved before too long, which will greatly facilitate model har-
monisation and a shift in focus towards integrated intervention
programmes.
5. Endemic country perspectives
Mathematical models may also inform country-specific deci-
sions about vaccine introduction, although interpretation of the
results must always be put in the context of local data quality
and uncertainty in model predictions. There are a number of efforts
to model dengue and vaccine impact locally to inform decision-
making. In these efforts, local priorities and questions for dengue
vaccine programs can best be taken into account.
To date, there has been no published systematic survey of what
dengue endemic countries most desire as outcomes from a dengue
vaccine program. Feedback from endemic country clinical and pub-
lic health professionals suggests a desire for a vaccine-mediated
reduction in the number of fatal cases and those requiring hospi-
talisation. This priority is driven by multiple realities. First, hospi-
talised case incidence can be measured by existing surveillance
systems and hence endemic countries have an available tool to
measure and communicate to their internal stakeholders the
impact of vaccination, i.e. a vaccine interrupted time series.
Second, the public perception of dengue as a public health problem
is driven partly by media reports and images of large caseloads in
hospital settings; these make for strong visual messages that
undermine community confidence in the competence of
government to manage public health. Third, hospitalised cases
account for much of the economic cost of dengue to health care
systems. Against this backdrop it is reasonable to assume that
endemic countries require, at a minimum, that a dengue vaccine
will deliver reductions in fatal and hospitalised cases. These
priorities should be reflected in vaccine modelling efforts, which
can allow policy makers to consider the potential impact of various
interventions utilised as a component of their overall dengue
control programme. Given the competing demands for financing,
modelling efforts could ultimately help countries design the
optimal dengue control program package, considering local dengue
epidemiology and resource constraints. This, however, crucially
relies on more effort being put into improving communication
between the modellers and policy makers as well as the
development of more user-friendly models for countries to use in
decision-making.
6. Enhancing input from mathematical models into vaccine
decision making
Different models make different, and often untested or unvali-
dated assumptions about the key drivers of dengue epidemiology
and vaccine performance due to underlying uncertainties. In order
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for policy makers to understand the assumptions, allowing their
own evaluation of the integrity of the results and confidence in
the model predictions, it is important that sufficient detail is pro-
vided on the model assumptions and parameters. These include
assumptions for infection states, disease states, serotype or strain
differences, transmission, vaccine response, vector, seasonality,
and spatial aspects (Box 1). A possible strategy for reporting based
on supporting of an archive of vector-borne disease models and
using an online questionnaire for researchers to fill in their model
specifications and key features. As mentioned earlier, reproducibil-
ity of model results is imperative to improve transparency and
enable comparisons between different approaches. Models should
therefore be described in sufficient details, including initial condi-
tions and the data used to inform and/or justify their choice of
parameter values.
7. Concluding remarks
The availability of epidemiological and clinical data from the
Phase III efficacy trials of Sanofi Pasteur’s tetravalent dengue vac-
cine has provided a great opportunity for mathematical models
to make semi-quantitative predictions about expected outcomes,
including short-term reduction in disease burden as well as poten-
tial unintended effects. Point estimates for vaccine efficacy, partic-
ularly those that are variable by serotype, age, host immune status,
and severity, only provide one kind of information to policy-
makers considering vaccination in their specific setting. Mathe-
matical models are valuable tools to translate these data into
country- or region-specific impact estimates as an additional input
into the policy-making process. However, data sharing and com-
munication with policy-makers, especially regarding the extent
and nature of uncertainties are critical for the success of mathe-
matical models to provide the best possible predictions and to
maximise their use health policy recommendations.
Box 1 Reporting requirements for dengue transmission models of vaccine
impact to improve transparency.
 Infection states
How many serotypes are considered in the model and
how many possible infections are assumed? Following
an infection, what are the assumptions about the infec-
tiousness and susceptibility of every subsequent infec-
tion? Details about the infection state should also
extend to the vector (if explicitly modelled) and their
interactions with the host should be detailed. Finally,
what are the assumptions regarding cross-protection
and/or cross-enhancement?
 Disease states
Details should be provided about the modelled out-
come of an infection (e.g. in terms of clinically apparent
disease or hospitalisation). Related to this, what is the
link between infection outcome and infectiousness?
Furthermore, does the probability of disease change
with subsequent infections and/or is it a function of
other model states, such as age or immunisation?
 Serotype or strain differences
Does the model assume heterogeneities in the trans-
missibility and/or pathogenicity between serotypes or
(if considered) between different strains? Are there het-
erogeneities in terms of cross-protection and/or cross-
enhancement? Equally, are vaccine efficacies assumed
to be symmetric or different for different serotypes?
 Transmission
What are the assumptions underlying the transmission
coefficients (e.g. biting rate, transmission probabilities,
etc.)? What is the assumed basic reproductive number
and what data is that based on? Are vectors explicitly
modelled in the model, which would warrant a descrip-
tion of human? vector and vector? human transmis-
sion probabilities? And for more detailed models,
temporal and spatial contact structures should be
described if assumptions are made regarding age- or
location-dependent probabilities of infection.
 Vaccine response
What assumptions are made regarding the action of a
vaccine, e.g. ’all-or-nothing’ (i.e. the vaccine offers
complete protections to some part of the population
but not the other) or ’leaky’ (i.e. vaccine offers partial
protection to every vaccinated individual)? Does vacci-
nation have an effect on infection, disease or both? Are
there serotype/strain- or age-dependent differences?
How does the immune status prior to immunization
affect the vaccine response? Finally, does the response
vary with time, e.g. during a multi-dose regime or
because of waning immunity?
 Vector
If vectors are explicitly modelled, what is their relative
population size? What mosquito life-stages are consid-
ered and what states are considered in terms of their
infection status? How their natural histories are rea-
lised and are there temporal variabilities in demogra-
phy? How should heterogeneous, focal transmission,
which arises from the biology and landscape on which
mosquito biting and pathogen transmission unfold, be
modelled? Attention should focus on the ecological
and social context of mosquito biting behaviour.
 Seasonality
How is seasonality incorporated in the model, e.g. tem-
poral variation in biting rates, temporal variability in
population densities and/or temporal variability in
incubation rates and how are these parameterised?
 Parameterisation
The data used for parameterising the model should be
described in sufficient details and, where possible,
either with references to published literature or better
included. Details about inference/algorithm used to
parameterise the data should also be supplied.
 Spatial aspects
Where applicable, details about spatial processes
should be described in sufficient details, including host
and vector movement and contact patterns, ecological
heterogeneities.
 Uncertainties and model sensitivity
How do the results depend on any of the above
assumptions? What are the major uncertainties under-
lying the model and the reported results? Has a
sensitivity analysis been carried out, and does it
cover model structure and/or model parameter
uncertainties?
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